Navigation Links
Sir Richard Sykes Joins BioCeramic Therapeutics as Chairman
Date:10/27/2008

Smart Materials Medtech Company Strengthens Board as Lead Products Approach

Clinic

LONDON, October 27 /PRNewswire/ -- UK medical technology company BioCeramic Therapeutics Ltd is delighted to announce that Sir Richard Sykes has accepted the role of Chairman of its Board of Directors. Sir Richard, former Chairman of pharmaceuticals company GlaxoSmithKline plc, takes up the post with immediate effect.

BioCeramic Therapeutics Ltd is a spinout from Imperial College in London, where Sir Richard was Rector until earlier this year.

BCT is a pioneer in the exciting new field of regenerative medicine, bringing together some of the world's best materials scientists doctors, biologists and chemists in both private and public sectors. BCT is developing two families of implants designed to promote tissue regeneration. Initial applications are in orthopaedics and oral care, with plans to extend this to a wide range of other tissues important in human diseases.

Daniel Green, BCT's CEO, said: "Sir Richard's immense experience and expert guidance will be invaluable as we move to the next stage of our growth plan: taking our lead development products to a stage where they benefit the public."

About BioCeramic Therapeutics Ltd

BioCeramic Therapeutics Ltd is a regenerative medicine company. Regenerative medicine's goal is to promote the body's natural tissue regeneration capabilities. We have proprietary biologically active materials that can be implanted or incorporated into other products. Initial markets are orthopedics and oral care, and our goal is to be able to regenerate many tissue types.

The underlying science is based on the work of Professor Molly Stevens, Research Director for Biomedical Material Sciences in the Institute for Biomedical Engineering and the Department of Materials at Imperial College, London and Prof Robert Hill and Dr Julian Jones, of the Department of Materials at Imperial College.

Based on their work, BCT is developing two generations of products. The first generation (BCT-000 series) is a series of modified bioactive glasses. The glasses incorporate carefully controlled amounts of strontium and other ingredients. Their role is to promote tissue growth, ensure resorption over time and inhibit pathogens. In addition, the right formulations enable their deployment as filler materials, bioactive coatings, or as flexible and tough rods and blocks with structural strength. These effects can be tailored to applications in each of our target markets to deliver decisive advantages over our competitors' products.

The second generation is a series of materials (BCT-100 series) is structured on a nano-scale to mimic the extracellular matrix. This generation moves beyond the capabilities of bioactive ceramics to address vastly larger markets in soft tissue repair. This programme has been awarded substantial grant-aid whose goal is an in vivo proof of principle.

http://www.bioceramictherapeutics.com


'/>"/>
SOURCE BioCeramic Therapeutics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Trusted LASIK Surgeons Welcomes Mobile Alabama Expert Refractive Eye Surgeon Richard Duffey, M.D. to Its LASIK Directory For Consumers
2. Abt Associates Names Richard Small Vice President and Chief Financial Officer
3. Cytochroma Appoints R. Richard Wieland II As CFO
4. Richard A. Schatz, M.D. Joins Cardiums Scientific Advisory Board
5. Mr. Richard Decker Appointed Technical Director of Edgewood Chemical Biological Center
6. 5AM Ventures Announces Expansion of Investment Team: Names Richard Ulevitch Venture Partner; Promotes Kevin Forrest and Andrew McMillan to Principal
7. Genetic Immunity Announces the Appointment of Richard B. Pollard, M.D. as Chief Medical Officer
8. Clinical and Economical Considerations For IV Push Drug Delivery by Industry Expert Richard Rosenfeld Is Now Accessible on Expert411.com for Media and Professional Use
9. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
10. Senior Research Analyst Richard Evans Joins AVOS Life Sciences
11. Richard Schulz Receives the Coveted GCPj Award for Best Clinical Researcher of the Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Palo Alto, CA, USA (PRWEB) , ... October 11, 2017 , ... ... is set to take place on 7th and 8th June 2018 in San Francisco, ... and policy influencers as well as several distinguished CEOs, board directors and government officials ...
(Date:10/11/2017)... ... ... Disappearing forests and increased emissions are the main causes of the evolving air ... living in larger cities are affected by air pollution related diseases. , That is ... globally - decided to take action. , “I knew I had to take action ...
(Date:10/10/2017)... Angeles, CA (PRWEB) , ... ... ... Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, ... uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in ...
(Date:10/10/2017)... , Oct. 10, 2017 SomaGenics announced the ... NIH to develop RealSeq®-SC (Single Cell), expected to be ... small RNAs (including microRNAs) from single cells using NGS ... the need to accelerate development of approaches to analyze ... "New techniques for measuring levels of mRNAs ...
Breaking Biology Technology:
(Date:5/6/2017)... 5, 2017 RAM Group , ... new breakthrough in biometric authentication based on a ... properties to perform biometric authentication. These new sensors are ... created by Ram Group and its partners. This sensor ... supply chains and security. Ram Group is a ...
(Date:4/18/2017)... 18, 2017  Socionext Inc., a global expert in SoC-based imaging ... server, the M820, which features the company,s hybrid codec technology. A ... Tera Probe, Inc., will be showcased during the upcoming Medtec Japan ... at the Las Vegas Convention Center April ... Click here for ...
(Date:4/13/2017)... India , April 13, 2017 According to ... Proofing, Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, ... MarketsandMarkets™, the IAM Market is expected to grow from USD 14.30 Billion ... Growth Rate (CAGR) of 17.3%. ... MarketsandMarkets ...
Breaking Biology News(10 mins):